Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: A review

NeuroRehabilitation

Volumn 31, Issue 2, 2012, Pages 117-129

  Intiso, Domenico ^a   Basciani, M ^a  

^a Neuro Rehabilitation Unit   (Italy)

Author keywords

Botulinum toxin; neuro rehabilitation; obstetrical brachial plexus palsy; sialorrhea

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ACETYLCHOLINE RELEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; BODY POSTURE; BRACHIAL PLEXUS; CAREGIVER; CEREBRAL PALSY; CHEWING DIFFICULTY; CLINICAL EVALUATION; DIARRHEA; DISABILITY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; FACIAL NERVE PARALYSIS; FAMILY; GAIT DISORDER; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; INJECTION SITE REACTION; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NECK PAIN; NERVE PARALYSIS; NEUROLOGIC DISEASE; NEUROREHABILITATION; OBSTETRIC BRACHIAL PLEXUS PALSY; OBSTETRICAL BRACHIAL PLEXUS PALSY; OCCUPATIONAL THERAPY; PAIN; PARKINSON DISEASE; PHYSICIAN; PHYSIOTHERAPY; PISA SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; REVIEW; SALIVARY GLAND; SUBMANDIBULAR GLAND; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCER; VISCOUS SALIVA; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; BRACHIAL PLEXUS NEUROPATHIES; CEREBRAL PALSY; HUMANS; NERVOUS SYSTEM DISEASES; SIALORRHEA;

EID: 84866900506     PISSN: 10538135     EISSN: 18786448     Source Type: Journal    
DOI: 10.3233/NRE-2012-0781     Document Type: Review

References (66)

1. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, Clarke J, Sakel M, Ampong MA, Shaw CE, Leigh PN, Al-Chalabi A (2007). Amyotrophic Lateral Sclerosis in South-East England: A Population based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology 29: 44-8.
2. Alrefai AH, Aburahma SK, Khader YS (2009). Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clinical Neurology and Neurosurgery 111(1): 79-82.
3. Arezzo JC (2009). NeuroBloc/Myobloc: unique features and findings. Toxicon 54: 690-696.
4. Bachrach SJ,Walter RS, Trzcinski K (1998). Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clinical Pediatrics 37: 485-490.
5. Backe B, Magnussen EB, Johansen OJ, Sellaeg G, Russwurm H (2008). Obstetric brachial plexus palsy: a birth injury not explained by the known risk factors. Acta Obstetricia et Gynecologica Scandinavica 87: 1027-32.
6. Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D (2011). Botulinum toxin type B for sialorrhea in children with cerebral palsy: a randomized trial comparing three doses. Developmental Medicine and Child Neurology 53(6): 559-64.
7. Basciani M, Intiso D, Cioffi RP, Tonali P (2000). Preoperative treatment with botulinum A toxin in patients with cervical disk herniation secondary to dystonic cerebral palsy. Neurological Sciences 21: 63.
8. Basciani M, Intiso D (2006). Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy. Pediatric Rehabilitation 9(2): 165-70.
9. Berweck S, Schroeder AS, Lee SH, Bigalke H, Heinen F (2007). Secondary non-reponse due to antibodies formation in a child after three injections of botulinum toxin B into salivary glands. Developmental Medicine Child Neurology: 62-64.
10. Bothwell JE, Clarke K, Dooley JM, Gordon KE, Anderson R, Wood EP, Camfield CS, Camfield PR (2002). Botulinum toxin A as a treatment for excessive drooling in children. Pediatric Neurology 27(1): 18-22.
11. BradleyWG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, Miller RG; ALS CARE Study Group (2001). Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. Neurology 57: 500-504.
12. Chen Y, Thalayasingam P (2010). Botulinum toxin to control an incapacitating tic in a child with a clavicular fracture. Anaesthesia and Intensive Care 38(6): 1106-8.
13. Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, Rapaccini GL, Gasbarrini G, Tonali PA, Bentivoglio AR. (2007) Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism and Related Disorders 13: 299-303.
14. Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M (2008). Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. Journal of Neurology 255(4): 545-50.
15. Crowner BE, Torres-Russotto D, Carter AR, Racette BA (2010). Systemic weakness after therapeutic injection of botulinum toxin A: a case series and review of the literature. Clinical Neuropharmacology 33: 243-247.
16. DasGupta BR (1994). Structures of botulinum neurotoxin. Its functional domains and perspectives on the crystalline tipe A toxin. In Jankovic J, Hallet M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker, 1994: 15-39.
17. DeMatteo C, Bain JR, Galea V, Gjertsen D (2006). Botulinum toxin as an adjunct to motor learning therapy and surgery for obstetrical brachial plexus injury. Developmental Medicine and Child Neurology 48: 245-52.
18. Desiato MT, Risina B (2001). The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy. Pediatric Rehabilitation 4: 29-36.
19. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004). Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clinical Neurology and Neurosurgery 106: 93-96.
20. Dressler D, Adib Saberi F, Benecke R (2002). Botulinum toxin type B for treatment of axillar hyperhidrosis. Journal of Neurology 249: 1729-1732.
21. Dressler D, Eleopra R(2006). Clinical use of non-A botulinum toxins: Botulinum toxin type B. Neurotoxicity Research 9: 121-125.
22. Ellies M, Rohrbach-Volland S, Arglebe C,Wilken B, Laskawi R, Hanefeld F (2002). Successful management of drooling with botulinum toxin A in neurologically disabled children. Neuropediatric 33(6): 327-30.
23. Esquenazi A (2006). Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. European Journal of Neurology 13(Suppl. 4): 27-34.
24. Foad SL,Mehiman CT, Ying J (2008). The epidemiology of neonatal brachial plexus palsy in the United States. Journal of Bone and Joint Surgery Am 90: 1258-64.
25. Friedman A, Potulska A (2001). Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism and Related Disorders 7: 329-332.
26. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV (2000). Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 69: 121-123.
27. Gilio F, Iacovelli E, Frasca V, Gabriele M, Giacomelli E, Picchiori F, Soldo P, Cipriani AM, Ruoppolo G, Inghilleri M (2010). Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotrophic Lateral Sclerosis 11(4): 359-63.
28. Gobets D, Beckerman H, de Groot V, Van Doorn-Loogman MH, Becher JG (2010). Indications and effects of botulinum toxin A for obstetric brachial plexus injury: a systematic literature review. Developmental Medicine and Child Neurology 52(6): 517-28.
29. Grossman JA, Price AE, Tidwell MA, Ramos LE, Alfonso I, Yaylali I (2003). Outcome after later combined brachial plexus and shoulder surgery after birth trauma. Journal of Bone and Joint Surgery Br 85B: 1166-8.
30. Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascian a R, Siciliani L, Sabatelli M, Bentivoglio AR (2011). Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Movement Disorders 26(2): 313-9.
31. Heise CO, Goncalves LR, Barbosa ER, Gherpelli JL (2005). Botulinum toxin for treatment of co-contractions related to obstetrical brachial plexopathy. Arq Neuropsiquiatr 63: 588-91.
32. HoeksmaAF,Wolf H, Oei SL (2000). Obstetric brachial plexus injuries: incidence, natural course and shoulder contracture. Clinical Rehabilitation 14: 523-6.
33. Hyson HC, Johnson AM, Jog MS (2002). Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Movement Disorders 17: 1318-1320.
34. Intiso D, Basciani M, Di Rienzo F, Tolfa M, Grimaldi G, Fiore P (2008). Botulinum toxin type A in the healing of ulcer following oro-mandibular dyskinesia in a patient in a vegetative state. Journal of Rehabilitation Medicine 40(4): 315-6.
35. Intiso D, BascianiM. Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury (2009). Journal of Rehabilitation Medicine 41(13): 1100-2.
36. Intiso D (2012). Therapeutic use of Botulinum toxin in Neurorehabilitation. Journal of Toxicology: 802893.
37. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, McVey A, Kittrell PP, King R, Herbelin L. and Muscle Study Group (2009). Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 39: 137-143.
38. JostWH (1999). Treatment of drooling in Parkinson's Disease with botulinum toxin. Movement Disorders 14: 1057-1059.
39. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2006). Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Movement Disorders 21: 704-707.
40. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2009). Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. Journal of Neurology 256: 563-7.
41. Lin YC, Shieh JY, Cheng ML, Yang PY (2008). Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy. Neurology 70(4): 316-8.
42. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003). A randomized trial of botulinum toxin A for the treatment of drooling. Neurology 61: 1279-1281.
43. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C (2003). Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Movement Disorders 18: 685-688.
44. Manrique D (2005). Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Rev Bras Otorrinolaringol (Engl Ed) 71: 566-569.
45. NobregaAC, Rodrigues B, TorresAC, Enzo A, MeloA(2007). Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease? Journal of Neurological Sciences 15;253(1-2): 85-7.
46. Ondo WG, Hunter C, Moore W (2004). A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62: 37-40.
47. Pal PK, Calne DB, Calne S, Tsui JK (2000). Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54(1): 244-7.
48. Price AE, Di Taranto P, Yaylali I, Tidwell MA, Grossman JA (2007). Botulinum toxin type A as an adjunct to the surgical treatment of the medial rotation deformity of the shoulder in birth injuries of the brachial plexus. Journal of Bone and Joint Surgery Br 89: 327-9.
49. Proulx M, de Courval FP, Wiseman MA, Panisset M (2005). Salivary production in Parkinson's disease. Movement Disorders 20: 204-247.
50. Racette BA, Good L, Sagitto S, Perlmutter JS (2003). Botulinum toxinBreduces sialorrhea in parkinsonism. Movement Disorders 18(9): 1059-61.
51. Reid SM, Johnstone BR,Westbury C, Rawicki B, Reddihough DS (2008). Randomized trial of botulinum toxin injections into salivary glands to reduce drooling in childrenwith neurological disorders. Developmental Medicine and Child Neurology 50(2): 123-8.
52. Rollnik JD, Hierner R, Schubert M, Shen ZL, Johannes S, Troger M, Wohlfarth K, Berger AC, Dengler R (2000). Botulinum toxin treatment of co-contractions after birth-related brachial plexus lesions. Neurology 12;55(1): 112-4.
53. Santamato A, Ianieri G, Ranieri M, Megna M, Panza F, Fiore P, Megna G (2008). Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease. Journal of American Geriatric Society 56(4): 765-7.
54. Santamato A, Panza F, Solfrizzi V, Frisardi V, Moretti B, Notarnicola A, Neve A, Ranieri M, Fiore P (2009). Botulinum toxin type A in the treatment of focal hand dystonia after surgical treatment for thumb duplication. Orthopedics 32(7): 529.
55. SantamatoA,Ranieri M, Panza F, Zoccolella S, FrisardiV, Solfrizzi V, AmorusoMT,Amoruso L, Fiore P (2010). Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. Journal of Neurology 257(1): 139-41.
56. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C (1992). Tetanus and boulinum -B neurotoxin block neurotransmitter release by a proteolytic cleavage of synapto-brevin. Nature 359: 832-835.
57. Scott KR, Kothari MJ, Venkatesh YS, Murphy T, Simmons Z (2005). Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis. Journal of Clinical Neuromuscular Disease 7: 62-65.
58. Shaw L, Rodgers H, Price C, vanWijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators (2010). BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technology Assessment 14(26): 1-113.
59. Stanton JS, Bainbridge LC (2002). The use of botulinum toxin for the internal rotation contracture of the shoulder in obstetric brachial plexus palsy. Arch Pharmacol 365(Suppl. 2): R44.
60. Su CS, Lan MY, Liu JS, Chang CC, Lai SL, Wu HS, Chen SS, Chang YY (2006). Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea. Acta Neurologica Taiwanica 15(3): 170-6.
61. Tan EK, Lo YL, Seah A, Auchus AP (2001). Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Journal of Neurological Sciences 15;190(1-2): 95-7.
62. TiltonA,Vargus-Adams J,DelgadoMR(2010). Pharmacologic Treatment of Spasticity in Children. Seminars in Pediatric Neurology 7: 261-267.
63. Toffola ED, Furini F, Redaelli C, Prestifilippo E, Bejor M (2010). Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disability and Rehabilitation 32(17): 1414-8.
64. Verma A, Steele J (2006). Botulinum toxin improbe sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 34: 235-237.
65. Wissel J,Ward AB, Erztgaard P, Bensmail D, HechtMJ, Lejeune TM, Schnider P, Altavista MC, Cavazza S, Deltombe T, Duarte E, Geurts AC, Gracies JM, Haboubi NH, Juan FJ, Kasch H, Kaotterer C, Kirazli Y, Manganotti P, Parman Y, Paternostro-Sluga T, Petropoulou K, Prempeh R, Rousseaux M, Slawek J, Tieranta N (2009). European consensus table on the use of botulinum toxin type A in adult spasticity. Journal of Rehabilitation Medicine 41(1): 13-25.
66. Worms PM (2001). The epidemiology of motor neuron diseases: a review of recent studies. Journal of the Neurological Sciences 191(1-2): 3-9.